Drug recall · February 24, 2021
Auryxia recall
Why: Failed Dissolution Specifications
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Auryxia (ferric citrate) tablets, 210 mg*, 200 tablets bottle, RX ONLY, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., 245 First Street, Suite 1400, Cambridge, MA 02142, USA, NDC 59922-0631-01.
- Lots / codes
Lots #: CDKSN, CDPPH, Exp January 2022; Lot #: CDPPK, Exp February 2022.
- Quantity
- 17,664 bottles
- Company
- Akebia Therapeutics dba Keryx Biopharmaceutials, Inc, Cambridge, MA
- Distribution
- Nationwide.
- Initiated
- January 29, 2021 · Voluntary: Firm initiated
- Classified
- February 17, 2021
- Reported
- February 24, 2021
- Ended
- February 10, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Auryxia
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.